BMS Prepares To Move Opdivo Into Neoadjuvant Lung Cancer
BMS reports event-free survival advantage, adding to earlier findings that Opdivo plus chemotherapy met statistical significance for pathologic complete response in the CheckMate-816 study.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.